Solebury Trout is working with the investment community for Novavax, which has announced its COVID-19 vaccine has a 93 percent efficacy rate against the virus.
Stanley Erck, CEO of the Gaithersburg, MD biotech, said Novavax “is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines."
The firm plans to file for regulatory approval for its NVX-CoV2373 vaccine in the third quarter.
Once approved, Novavax said it will be able to produce 100M shots a month by the end of Q3 and 150 doses by year-end.
Novavax, which is 33 years old, has never had a vaccine approved by the Food and Drug Administration.
Solebury Trout’s Alexandria Roy represents Novavax.